枳术六君子汤联合GP 方案对非小细胞肺癌患者癌因性疲乏的影响
DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R734.2

基金项目:


Effect of Zhizhu Liujunzi Decoction Combined with GP Regimen on Cancer-Related Fatigue in Non-Small Cell Lung Cancer Patients
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察枳术六君子汤联合GP方案对非小细胞肺癌(NSCLC) 患者癌因性疲乏(CRF) 的影 响。方法:采用随机数字表法将110例NSCLC患者分为对照组、治疗组各55例。对照组给予GP方案治疗,治 疗组给予GP 方案联合枳术六君子汤治疗。比较2 组治疗前后中医证候评分、舌苔厚度评分、癌症疲乏量 表(CFS) 评分及T淋巴细胞、血清肿瘤因子水平,并评估2组临床疗效及不良反应发生情况。结果:治疗后, 治疗组疾病控制率(DCR) 为94.55%,对照组DCR为81.82%,治疗组DCR高于对照组(P<0.05)。2组治疗 后中医证候评分、舌苔厚度评分、CFS评分、细胞角蛋白19片段21-1(CYFRA21-1)、糖类抗原(CA125)、癌 胚抗原(CEA)、神经元特异性烯醇化酶(NSE) 及CD8+水平均低于治疗前(P<0.05),且治疗组中医证候评 分、舌苔厚度评分、CFS评分、CYFRA21-1、CA125、CEA、NSE及CD8+水平均低于对照组(P<0.05)。2组治 疗后CD3+、CD4+水平及CD4+/CD8+均高于治疗前(P<0.05),且治疗组CD3+、CD4+水平及CD4+/CD8+高于对照 组(P<0.05)。治疗组不良反应发生率34.55%,低于对照组54.55% (P<0.05)。结论:枳术六君子汤联合 GP方案治疗NSCLC疗效确切,能够缓解患者CRF症状,调节免疫功能,降低血清肿瘤因子水平,安全性较高。

    Abstract:

    Abstract:Objective:To observe the effect of Zhizhu Liujunzi Decoction combined with GP regimen on cancer-related fatigue (CRF) in patients with non-small cell lung cancer (NSCLC). Methods: A total of 110 NSCLC patients were divided into the control group and the treatment group, with 55 cases in each group, using a random number table method. The control group was treated with GP regimen, and the treatment group was treated with GP regimen combined with Zhizhu Liujunzi Decoction. Compared the traditional Chinese medicine (TCM) syndrome scores, tongue coating thickness scores, Cancer Fatigue Scale (CFS) scores,and levels of T lymphocytes and serum tumor factors before and after treatment in the two groups, and evaluated the clinical efficacy and incidence of adverse reactions in the two groups. Results: After treatment, the total disease control rate (DCR) was 94.55% in the treatment group, and 81.82% in the control group,and the DCR of the treatment group was higher than that of the control group (P<0.05). After treatment, the TCM syndrome scores, tongue coating thickness scores, CFS scores, cytokeratin fragment 21-1 (CYFRA21-1),carbohydrate antigen (CA125),carcinoembryonic antigen (CEA), neuron specific enolase (NSE) and CD8+ levels in both groups were lower than those before treatment (P< 0.05), and the TCM syndrome score, tongue coating thickness score, CFS score, CA125, CEA, CYFRA21-1, NSE and CD8+ level in the treatment group were lower than those in the control group (P< 0.05). After treatment,the levels of CD3+, CD4+, and CD4+/CD8+ in both groups were higher those than before treatment (P<0.05), and the levels of CD3+, CD4+, and CD4+/CD8+ in the treatment group were higher than those in the control group (P<0.05). The incidence of adverse reactions was 34.55% in the treatment group, lower than that of 54.55% in the control group (P<0.05). Conclusion: Zhizhu Liujunzi Decoction combined with GP regimen has a definite therapeutic effect on NSCLC,which can alleviate CRF symptoms,regulate immune function,reduce serum tumor factor levels,and has high safety.

    参考文献
    相似文献
    引证文献
引用本文

毕旺伟,李晨曦,陈敏方.枳术六君子汤联合GP 方案对非小细胞肺癌患者癌因性疲乏的影响[J].新中医,2024,56(18):185-189

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2024-09-27
  • 出版日期: